Composition for reducing blood sugar as well as preparation method and application thereof

Abstract

The invention belongs to the technical field of food, and discloses a composition for reducing blood sugar as well as a preparation method and application thereof. The composition comprises the following effective components: 10 parts of animal protein, 15-25 parts of mulberry leaf extract, 5-10 parts of chromium-enriched yeast and 50-100 parts of inulin. The raw material components in the composition can achieve a synergistic effect, the purpose of reducing blood sugar is achieved, the preparation method is simple, and the cost is low.

Description

Technical Field

[0001] The invention belongs to the technical field of food, and relates to a blood sugar lowering composition, in particular to a blood sugar lowering composition, a preparation method and application thereof. Background Art

[0002] The blood sugar level of diabetic patients fluctuates greatly, especially after eating. The blood sugar level of diabetic patients rises sharply, which is easy to cause complications. At present, most diabetic patients choose to take hypoglycemic drugs or inject insulin before meals to reduce blood sugar fluctuations. However, although long-term use of hypoglycemic drugs can effectively control blood sugar and reduce the risk of diabetic complications, it also brings a series of side effects, such as thrombocytopenia, elevated transaminase, liver damage, gastrointestinal discomfort, anemia, etc.

[0003] In recent years, some hypoglycemic compositions have appeared one after another. These hypoglycemic compositions are composed of food raw materials and can be eaten as food. They can effectively reduce the side effects of hypoglycemic drugs on the basis of lowering blood sugar and have strong applicability.

[0004] How to innovate on the basis of hypoglycemic compositions to improve the hypoglycemic effect is currently a hot topic. Summary of the invention

[0005] In order to solve the above deficiencies in the prior art, the present invention aims to provide a blood sugar lowering composition, which is based on food raw materials and added with animal protein. When consumed before a meal, the composition can regulate postprandial blood sugar and fasting blood sugar to achieve the purpose of lowering blood sugar.

[0006] The present invention also provides a method for preparing a hypoglycemic composition, which has achieved the purpose of simple preparation process and low cost;

[0007] The present invention also provides an application of the blood sugar lowering composition.

[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0009] A blood sugar lowering composition, wherein the raw materials for making the effective components of the composition include, by weight: 10 parts of animal protein, 15-25 parts of mulberry leaf extract, 5-10 parts of chromium-enriched yeast and 50-100 parts of inulin.

[0010] As a limitation of the present invention, the animal protein consists of casein phosphopeptide and casein glycomacropeptide.

[0011] As a further limitation of the present invention, the weight ratio of casein phosphopeptide to casein glycomacropeptide is 1:4-9.

[0012] As a further limitation of the present invention, the weight percentage of 1-deoxynojirimycin in the mulberry leaf extract is 5%.

[0013] As a further limitation of the present invention, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin in the composition is 1:9:25:10:100.

[0014] The present invention also provides a method for preparing the above-mentioned hypoglycemic composition, comprising the following steps: taking the animal protein, mulberry leaf extract, chromium-enriched yeast, inulin and maltodextrin, and mixing them to obtain the hypoglycemic composition.

[0015] The present invention also provides the use of the composition obtained by the preparation method of the hypoglycemic composition in the preparation of granules, powders, capsules, tablets, injections, pills, powders or oral liquids for hypoglycemic agents.

[0016] Due to the adoption of the above technical solution, the present invention has the following beneficial effects compared with the prior art:

[0017] (1) The hypoglycemic composition of the present invention adds animal protein to food raw materials, and its effective ingredient raw materials include animal protein, mulberry leaf extract, chromium-enriched yeast, and inulin. Among them, mulberry leaf extract is a health food raw material, and 1-deoxynojirimycin (DNJ) in mulberry leaf extract is an α-glycosidase inhibitor, which can hinder the binding of disaccharides such as sucrose and maltose with α-glycosidase, reduce the glucose entering the blood, and thus reduce the body's absorption rate of common carbohydrates to varying degrees;

[0018] Inulin is a new food raw material. As a dietary fiber, it can slow down the speed at which glucose enters the blood after eating, thus controlling the rapid rise of blood sugar after a meal. In addition, the products of inulin fermentation in the intestine, especially propionic acid, may also indirectly affect blood sugar by affecting the absorption and metabolism of glucose. Chromium-rich yeast is a health food raw material. The chromium in it is trivalent chromium. As an effective active ingredient of glucose tolerance factor, it can increase the sensitivity of target tissues to insulin without promoting insulin secretion in the pancreas.

[0019] Animal protein has a low GI value and contains more high-quality amino acids. After intake, it can reduce the GI value of the overall food intake, slow down blood sugar fluctuations, and effectively regulate postprandial blood sugar;

[0020] The blood sugar lowering composition of the present invention is eaten as food, which can achieve the blood sugar lowering effect and has higher food safety.

[0021] (2) In the blood sugar regulating composition provided by the present invention, casein phosphopeptide and casein glycomacropeptide have the effect of regulating blood sugar at a certain ratio. The mechanism of action may be that a certain ratio of casein phosphopeptide and casein glycomacropeptide can not only provide energy supply for the body, but also improve the body's tolerance to glucose, increase the body's sensitivity to insulin, and effectively improve insulin resistance.

[0022] (3) In the present invention, casein phosphopeptide and casein glycomacropeptide are combined with mulberry leaf extract, chromium-rich yeast and inulin in a certain proportion to achieve a synergistic effect. The casein phosphopeptide, casein glycomacropeptide, mulberry leaf extract, chromium-rich yeast and inulin work together to enhance the hypoglycemic effect, thereby effectively regulating postprandial blood sugar and fasting blood sugar. When the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin in the composition is 1:9:25:10:100, the enhanced hypoglycemic effect is optimal, achieving better postprandial blood sugar and fasting blood sugar regulation effects.

[0023] (4) The preparation method of the hypoglycemic composition of the present invention is simple, the preparation cost is low, and the applicability is strong.

[0024] The invention is suitable for preparing a blood sugar lowering composition for consumption by diabetic patients before meals. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.

[0026] Figure 1 This is a graph showing the experimental results of the fasting blood sugar change value in the test for evaluating the improvement of blood sugar status of the present invention;

[0027] Figure 2 This is a graph showing the experimental results of the change in blood sugar 2 hours after a meal in the test for evaluating the improvement of blood sugar status of the present invention;

[0028] Figure 3 This is a schematic diagram of the change value of clinical symptom integral in the test for evaluating improvement of blood sugar status of the present invention. DETAILED DESCRIPTION

[0029] The present invention is further described in detail below through specific embodiments and drawings. It should be understood that the described embodiments are only used to explain the present invention, but not to limit the present invention.

[0030] Unless otherwise specified, the materials and reagents used in the examples of the present invention can be obtained from commercial sources. Experimental methods without specific conditions in the examples are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0031] Example 1 Preparation of a blood sugar lowering composition

[0032] The blood sugar lowering composition of this embodiment has the following raw materials: 30 g of casein phosphopeptide, 170 g of casein glycomacropeptide, 300 g of mulberry leaf extract, 150 g of chromium-enriched yeast and 1000 g of inulin; and 2350 g of maltodextrin is also taken.

[0033] In this embodiment, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 1.5:8.5:15:7.5:50.

[0034] The preparation method of the composition comprises the following steps: taking the above raw material components, mixing them evenly, and obtaining a composition for reducing blood sugar, which is in powder form and marked as Z1.

[0035] Example 2 Preparation of a blood sugar lowering composition

[0036] The blood sugar lowering composition of this embodiment comprises the following raw materials: 40 g of casein phosphopeptide, 160 g of casein glycomacropeptide, 400 g of mulberry leaf extract, 100 g of chromium-enriched yeast and 1500 g of inulin; and 1800 g of maltodextrin.

[0037] In this embodiment, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 2:8:20:5:75.

[0038] The preparation method of the composition comprises the following steps: taking the above-mentioned raw material components, mixing them evenly, and obtaining a composition for reducing blood sugar, which is in powder form and marked as Z2.

[0039] Example 3 Preparation of a blood sugar lowering composition

[0040] The blood sugar lowering composition of this embodiment comprises the following raw materials: 20 g of casein phosphopeptide, 180 g of casein glycomacropeptide, 500 g of mulberry leaf extract, 200 g of chromium-enriched yeast and 2000 g of inulin; and 1100 g of maltodextrin.

[0041] In this embodiment, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 1:9:25:10:100.

[0042] The preparation method of the composition comprises the following steps: taking the above-mentioned raw material components, mixing them evenly, and obtaining a composition for reducing blood sugar, which is in powder form and marked as Z3.

[0043] Example 4 Preparation of a blood sugar lowering composition

[0044] The blood sugar lowering composition of this embodiment has the following raw materials: 22 g of casein phosphopeptide, 178 g of casein glycomacropeptide, 500 g of mulberry leaf extract, 200 g of chromium-enriched yeast and 2000 g of inulin; and 1100 g of maltodextrin.

[0045] In this embodiment, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 1.1:8.9:25:10:100.

[0046] The preparation method of the composition comprises the following steps: taking the above raw material components, mixing them evenly, and obtaining a composition for reducing blood sugar, which is in powder form and marked as Z4.

[0047] Example 5 Preparation of a hypoglycemic composition

[0048] The blood sugar lowering composition of this embodiment has the following raw materials: 26 g of casein phosphopeptide, 174 g of casein glycomacropeptide, 480 g of mulberry leaf extract, 120 g of chromium-enriched yeast and 1200 g of inulin; and 2000 g of maltodextrin.

[0049] In this embodiment, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 1.3:8.7:24:6:60.

[0050] The preparation method of the composition comprises the following steps: taking the above raw material components, mixing them evenly, and obtaining a composition for reducing blood sugar, which is in powder form and marked as Z5.

[0051] Example 6 Preparation of a blood sugar lowering composition

[0052] The blood sugar lowering composition of this embodiment has the following raw materials: 20 g of casein phosphopeptide, 180 g of casein glycomacropeptide, 320 g of mulberry leaf extract, 180 g of chromium-enriched yeast and 1800 g of inulin; and 1500 g of maltodextrin.

[0053] In this embodiment, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 1:9:16:9:90.

[0054] The preparation method of the composition comprises the following steps: taking the above raw material components, mixing them evenly, and obtaining a composition for reducing blood sugar, which is in powder form and marked as Z6.

[0055] Comparative Example 1 Preparation of a Composition

[0056] The preparation method of the composition in this comparative example is the same as the preparation method of Example 3, except that the amount of casein phosphopeptide is 200 g and the amount of casein glycomacropeptide is 0. The obtained composition is in powdery form and is marked as DZ1.

[0057] In this comparative example, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 10:0:25:10:100.

[0058] Comparative Example 2 Preparation of a Composition

[0059] The preparation method of the composition in this comparative example is the same as the preparation method of Example 3, except that the amount of casein phosphopeptide is 0 and the amount of casein glycomacropeptide is 200 g. The obtained composition is in powdery form and is marked as DZ2.

[0060] In this comparative example, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 0:10:25:10:100.

[0061] Comparative Example 3 Preparation of a Composition

[0062] The preparation method of the composition in this comparative example is the same as the preparation method of Example 3, except that the amount of casein phosphopeptide is 50 g and the amount of casein glycomacropeptide is 150 g. The obtained composition is in powdery form and is marked as DZ3.

[0063] In this comparative example, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 2.5:7.5:25:10:100.

[0064] Comparative Example 4 Preparation of a Composition

[0065] The preparation method of the composition in this comparative example is the same as the preparation method of Example 3, except that the amount of casein phosphopeptide is 18 g and the amount of casein glycomacropeptide is 182 g. The obtained composition is in powdery form and is marked as DZ4.

[0066] In this comparative example, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 0.9:9.1:25:10:100.

[0067] Comparative Example 5 Preparation of a Composition

[0068] The preparation method of the composition in this comparative example is the same as that of Example 3, except that the amount of inulin is 2200 g and the amount of maltodextrin is 900 g. The obtained composition is in powdery form and is marked as DZ5.

[0069] In this comparative example, the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin is 1:9:25:10:110.

[0070] Improvement of blood sugar status evaluation test

[0071] (1) Recruitment of subjects: Subjects were 18-65 years old, with impaired glucose regulation (IGR) with fasting blood glucose of 5.6-7 mmol / L or 2-hour postprandial blood glucose of 7.8-11.1 mmol / L. Subjects had no complications of diabetic nephropathy or were not taking glucose-lowering drugs containing acarbose, voglibose, or miglitol.

[0072] (2) Experimental method: A randomized double-blind controlled trial was conducted. 120 subjects were randomly selected and divided into 12 groups, with 10 subjects in each group, including experimental groups X1-X6, blank group Y0, and control group Y1-Y5.

[0073] Before the experiment, each subject was prescribed a corresponding diet according to their gender, age, different labor intensity, ideal body weight and original living habits. At the same time, ① the fasting blood sugar of each subject was measured, ② the blood sugar of each subject 2 hours after meal was measured, ③ the clinical symptoms of each subject were observed according to the clinical symptom score table (see Table 1), and the clinical symptom score was recorded.

[0074] Table 1 Clinical symptom score table

[0075]

[0076] During the trial, the patients adhered to the dietary control, and the types and dosages of drugs for the treatment of diabetes remained unchanged. The experimental group X1-X6, the blank group Y0, and the control group Y1-Y5 took Z1-Z6, maltodextrin, and DZ1-DZ5 5-10 minutes before lunch, respectively. The amount of consumption was 20g, and it was taken with warm water. After 8 weeks,

[0077] ①Measure the fasting blood sugar of each subject and compare it with the fasting blood sugar of the subject before the test. Statistical fasting blood sugar change values ​​are shown in Figure 1 ②Measure the blood sugar level of each subject 2 hours after meal and compare it with the blood sugar level of the subject 2 hours after meal before the test. Statistical analysis of the change of blood sugar level 2 hours after meal is shown in Figure 2 ③Observe the clinical symptoms of each subject and record the clinical symptom score, compare it with the clinical symptom score of the subject before the trial, and calculate the change value of the clinical symptom score. Figure 3 .

[0078] (5) Analysis of test results

[0079] Depend on Figure 1 and Figure 2It can be seen that there was no significant improvement in the indicators of the blank group Y0, and the fasting blood glucose change values ​​and 2h postprandial blood glucose change values ​​of the experimental groups X1-X6 were significantly better than those of the control groups Y1-Y5, indicating that when the weight ratio of animal protein composed of casein phosphopeptide and casein glycomacropeptide is 1:4-9: mulberry leaf extract: chromium-rich yeast: inulin is 10:15-25:5-10:50-100, the prepared blood sugar-lowering composition can significantly regulate blood sugar changes. Among them, the results of the experimental group X3 showed that when the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin in the composition is 1:9:25:10:100, the enhanced blood sugar-lowering effect is optimal.

[0080] The results of the experimental group X3 and the control group Y1-Y2 showed that when the animal protein consisted of either casein phosphopeptide or casein glycomacropeptide, the hypoglycemic effect of the obtained composition was reduced, indicating that in the composition of the present invention, both casein phosphopeptide and casein glycomacropeptide are indispensable, and the two act synergistically with mulberry leaf extract, chromium-rich yeast, and inulin to achieve a hypoglycemic effect.

[0081] The results of the experimental group X3 and the control group Y3-Y4 showed that when the weight ratio of casein phosphopeptide and casein glycomacropeptide was lower than or higher than 1:4-9, the hypoglycemic effect of the obtained composition was reduced. The reason may be that when the weight ratio of casein phosphopeptide and casein glycomacropeptide was lower than or higher than 1:4-9, the effects of both on improving insulin resistance were reduced, thereby reducing the hypoglycemic effect of the obtained composition.

[0082] The results of the experimental group X3 and the control group Y5 showed that when the weight ratio of inulin in the composition increased, the hypoglycemic effect did not change, indicating that the combination of excessive inulin with casein phosphopeptide and casein glycomacropeptide did not achieve a better hypoglycemic effect. The amount of inulin used in the present invention is reasonable while achieving the hypoglycemic effect, thereby saving costs.

[0083] Depend on Figure 3 It can be seen that the clinical symptoms of the blank group Y0 were not significantly improved, and the clinical symptoms of the experimental groups X1-X6 were significantly better than those of the control groups Y1-Y4, indicating that when the weight ratio of animal protein composed of casein phosphopeptide and casein glycomacropeptide is 1:4-9: mulberry leaf extract: chromium-rich yeast: inulin is 10:15-25:5-10:50-100, the five components are coordinated and synergistic, and the effect of improving clinical symptoms is best when eaten together. The results of the experimental group X3 and the control group Y5 showed that when the dosage of inulin was increased, the clinical symptoms could not be further improved, indicating that the dosage of inulin in the present invention is reasonable while achieving the effect of lowering blood sugar, thereby saving costs.

[0084] Example 7 Application of a blood sugar lowering composition

[0085] This embodiment is the use of a blood sugar lowering composition in the preparation of granules, powders, capsules, tablets, injections, pills, powders or oral liquids for lowering blood sugar.

[0086] The obtained hypoglycemic compositions Z1-Z6 are mixed, mixed evenly in a V-type mixer, conveyed to a boiling granulator, granulated with purified water, and dried at 100° C. to obtain small granular solids for consumption by diabetic patients before meals.

[0087] It should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention is described in detail with reference to the above embodiments, those skilled in the art can still modify the technical solutions described in the above embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the scope of protection of the claims of the present invention.

Claims

1. A blood sugar lowering composition, It is characterized in that The raw materials for making the effective components of the composition include, by weight: 10 parts of animal protein, 15-25 parts of mulberry leaf extract, 5-10 parts of chromium-enriched yeast and 50-100 parts of inulin.

2. The hypoglycemic composition according to claim 1, It is characterized in that The animal protein consists of casein phosphopeptide and casein glycomacropeptide.

3. The hypoglycemic composition according to claim 2, It is characterized in that The weight ratio of casein phosphopeptide to casein glycomacropeptide is 1:4-9.

4. The hypoglycemic composition according to claim 3, Features , the weight percentage of 1-deoxynojirimycin in the mulberry leaf extract is 5%.

5. The hypoglycemic composition according to claim 4, Features , the weight ratio of casein phosphopeptide: casein glycomacropeptide: mulberry leaf extract: chromium-rich yeast: inulin in the composition is 1:9:25:10:

100.

6. A method for preparing the hypoglycemic composition according to any one of claims 1 to 5, It is characterized in that The following steps are involved: The animal protein, mulberry leaf extract, chromium-enriched yeast, inulin and maltodextrin are mixed to obtain a blood sugar lowering composition.

7. Use of the composition obtained by the preparation method of the hypoglycemic composition according to claim 6 in the preparation of granules, powders, capsules, tablets, injections, pills, powders or oral liquids for hypoglycemics.

Images